Citizens for
Alternatives to Animal Research (CAARE)
May 2015
The 3D bioprinted liver model has the enormous potential to enhance drug safety by reducing side effects in humans that turn up in late-stage clinical trials. It also promises to reduce the time and cost burden of drug production and, over time, remove reliance on animals.
Merck & Co., one of the world’s largest pharmaceutical companies, is
teaming up with Organovo, a U.S. biotech firm specializing in manufacturing
3D printed tissues from human cells. The result, according to Organovo’s
website, is “structurally and functionally accurate bioprinted human tissue
models.”
The collaboration will allow Merck to utilize Organovo’s exVive3D Human
Liver Tissue service, which has the potential to replace the use of animals
in assessing liver toxicity for drug development. Initially Merck will use
the 3D Liver model as a supplement to animal tests, but may use it to
replace them over time.
The Novogen MMX Bioprinter® prints fully human, architecturally correct 3D
tissue (courtesy Organovo)
The Organovo liver model is composed of three different types of liver cells, as found in the normal human liver. The 3D bioprinting process allows the cells to use their innate abilities to align into a matrix, mimicking the natural architecture of the liver. This promotes the production of critical liver products, such as cholesterol, albumin and cytochrome P450, each of which plays an essential role in drug metabolism.
Bioprinted human liver tissue in 3 dimensions. (Courtesy Organovo)
Able to perform for up to 40 days, the Organovo liver model can study
chronic as well as acute side effects. These characteristics are not seen in
traditional 2D cell cultures.
In August 2014, Organovo released information demonstrating that its tissue
system was able to predict liver toxicity where animal tests had failed.
Organovo’s 3D liver model was used to test a drug that had been deemed safe
based on standard pre-clinical studies, including animal tests, but was
later shown to be toxic after being given to patients in a clinical trial.
The Organovo 3D Liver model detected the toxic effect – a critical advantage
over the standard cultures and animal tests.
The 3D bioprinted liver model has the enormous potential to enhance drug
safety by reducing side effects in humans that turn up in late-stage
clinical trials. It also promises to reduce the time and cost burden of drug
production and, over time, remove reliance on animals.
One of Organovo's tissue engineers oversees
the construction of a vascular tissue construct
on the Novogen MMX Bioprinter®. (Courtesy Organovo)
A company spokesperson tells CAARE that the collaboration with Merck also
involves developing “multiple custom tissue models utilizing the Company’s
proprietary NovoGen Bioprinting Platform™, for use in drug development."
The potential for this development to help humans and animals does not stop
there. Organovo is exploring the therapeutic use of engineered human tissue,
including building tissues for regenerative medicine and transplantation.
Although not a reality yet, the prospects for this technology to develop
living human tissue to treat a variety of diseases appear huge, potentially
changing the face of medicine, all without the use of animals.
Rabbit under a gloved hand in a lab...
Return to Alternatives to Animal Testing, Experimentation and Dissection
Read more at Animal Rights Articles